DNA Vaccine Administered by Cationic Lipoplexes or by In Vivo Electroporation Induces Comparable Antibody Responses against SARS-CoV-2 in Mice.
Allegra PelettaEakachai PrompetcharaKittipan TharakhetPapatsara KaewpangSupranee BuranapraditkunTeerasit TechawiwattanaboonTayeb JbilouPratomporn KrangvichianSunee SirivichayakulSuwimon ManopwisedjaroenArunee ThitithanyanontKanitha PatarakulKiat RuxrungthamChutitorn KetloyGerrit BorchardPublished in: Vaccines (2021)
In view of addressing the global necessity of an effective vaccine in the SARS-CoV-2 pandemic, a plasmid DNA vaccine, expressing for the spike (S) protein and formulated in lipoplexes, was manufactured and tested for in vitro transfection and in vivo immunogenicity. Blank cationic liposomes of 130.9 ± 5.8 nm in size and with a zeta potential of +48 ± 12 mV were formulated using the thin-film layer rehydration method. Liposomes were complexed with pCMVkan-S at different N/P ratios. Ratios of 0.25:1 and 1:1 were selected according to their complex stability and controlled size compared to other ratios and tested in vitro for transfection studies and in vivo for immunogenicity. Both selected formulations showed enhanced neutralizing antibody responses compared to pCMVkan-S injected alone, as well as an increased T cell response. The titers observed were similar to those of intramuscular electroporation (IM-EP), which was set as an efficacy goal.
Keyphrases
- sars cov
- drug delivery
- respiratory syndrome coronavirus
- circulating tumor
- cell free
- single molecule
- escherichia coli
- drug release
- coronavirus disease
- photodynamic therapy
- crispr cas
- nucleic acid
- risk assessment
- high fat diet induced
- small molecule
- human health
- insulin resistance
- case control
- binding protein
- circulating tumor cells